Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report 2026

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview

• Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis market size has reached to $0.63 billion in 2025 • Expected to grow to $0.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Autoimmune Disease Cases Fuels The Market Growth Due To Demand In Advanced Treatments And Early Diagnostics • Market Trend: Advancing Targeted Therapies for ANCA-Associated Vasculitis Treatment and Disease Control • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?

Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare, autoimmune disorder characterized by inflammation and damage to small and medium-sized blood vessels, primarily affecting organs such as the kidneys, lungs, and respiratory tract, often leading to severe complications if left untreated. This condition is closely linked to nephrology, pulmonology, and rheumatology, requiring multidisciplinary management involving immunosuppressive therapies, corticosteroids, and advanced treatment strategies to prevent organ failure and improve long-term patient outcomes. The main types of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis are granulomatosis with polyangiitis (GPA or Wegener's), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), and others. Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, systemic, ANCA-associated vasculitis (AAV) characterized by inflammation of small to medium-sized blood vessels, leading to granuloma formation and damage primarily affecting the respiratory tract, kidneys, and other organs. It is managed by various treatments such as immunosuppressants, corticosteroids, biologics, and others, with the help of diagnosis including blood tests, biopsy, imaging, and others.

What Is The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Forecast?

The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of targeted biologics, rising investments in rare disease research, expansion of personalized treatment approaches, growing focus on relapse prevention strategies, increasing patient access to specialized care centers. Major trends in the forecast period include increasing adoption of biologic therapies, rising focus on early and accurate diagnosis, growing use of targeted immunosuppressive treatments, expansion of multidisciplinary disease management approaches, enhanced emphasis on long-term disease monitoring.

Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segmentation

1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener's), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), Other Types 2) By Treatment: Immunosuppressants, Corticosteroids, Biologics, Other Treatments 3) By Diagnosis: Blood Tests, Biopsy, Imaging, Other Diagnosis Subsegments: 1) By Granulomatosis With Polyangiitis (GPA or Wegener's): Limited Granulomatosis With Polyangiitis, Severe Granulomatosis With Polyangiitis, Refractory Granulomatosis With Polyangiitis 2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis, Pulmonary Microscopic Polyangiitis, Neurological Microscopic Polyangiitis 3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis, Pulmonary Eosinophilic Granulomatosis With Polyangiitis, Neurological Eosinophilic Granulomatosis With Polyangiitis 4) By Other Types: Drug-Induced ANCA-Associated Vasculitis, Infection-Related ANCA-Associated Vasculitis, Overlap Syndrome ANCA-Associated Vasculitis

What Is The Driver Of The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?

The rising incidence of autoimmune diseases is expected to drive the growth of the ANCA-associated vasculitis market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's healthy cells and tissues, thinking they are foreign invaders like bacteria or viruses. The rising incidence of autoimmune diseases is due to environmental triggers and lifestyle factors, with increasing exposure to infections and pollutants as a significant contributor by disrupting immune tolerance and triggering abnormal immune responses. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis plays a positive role in advancing autoimmune disease research and treatment by driving the development of targeted immunosuppressive therapies, enhancing early diagnostic capabilities, and improving overall disease management strategies, ultimately contributing to better patient outcomes and a deeper understanding of immune system regulation. For instance, in September 2023, according to the Impact of IBD Report 2023 published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization that aims to improve the lives of patients with Crohn's disease and ulcerative colitis, in 2023, the prevalence of inflammatory bowel disease (IBD) (an autoimmune diseases) in Canada was 825 per 100,000 people, affecting over 320,000 individuals. With an expected annual increase of 2.44% in prevalence, it is projected that by 2035, approximately 470,000 Canadians, representing 1.1% of the population, will be living with IBD. Therefore, the rising incidence of autoimmune diseases will drive the ANCA-associated vasculitis market.

Key Players In The Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

Major companies operating in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are ChemoCentryx Inc, Amgen Inc, AstraZeneca Plc, GlaxoSmithKline plc, Novartis AG, Bristol‑Myers Squibb Company, Travere Therapeutics Inc, F. Hoffmann‑La Roche AG, Pfizer Inc, Sanofi SA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AbbVie Inc, UCB S.A., Bayer AG, Janssen Pharmaceuticals NV, Sobi AB, Alentis Therapeutics AG, InflaRx NV, NS Pharma Inc, Staidson Biopharmaceuticals Co Ltd, Genentech Inc, Regeneron Pharmaceuticals Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, Biogen Inc, CSL Limited, Moderna Inc, Vertex Pharmaceuticals Inc.

Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Trends and Insights

Major companies operating in the ANCA-associated vasculitis market are focusing on developing innovative solutions, such as targeted therapies, to provide a new treatment option for patients with a rare and serious disease. Targeted therapy for ANCA-associated vasculitis involves using specialized biologic agents to selectively inhibit immune system components responsible for inflammation and vascular damage, thereby reducing disease progression and minimizing treatment-related toxicity. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical company, announced the approval of Tavneos (avacopan) by the Therapeutic Goods Administration (TGA), an Australia-based government regulatory agency, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), in combination with rituximab or cyclophosphamide-based regimen. This approval marks a significant advancement as Tavneos is the first targeted therapy designed explicitly for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two primary forms of ANCA-associated vasculitis. By selectively inhibiting the complement C5a receptor (C5aR1), the therapy helps control inflammation and disease progression while reducing the reliance on high-dose glucocorticoids (steroids), which are known for severe long-term side effects.

What Are Latest Mergers And Acquisitions In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?

In March 2024, Q32 Bio Inc., a US-based clinical-stage biotechnology company, merged with Homology Medicines, Inc. for an undisclosed amount. With this deal, Q32 Bio aims to strengthen its position as a public biotech company by securing funding to advance key biologic therapies bempikibart for autoimmune diseases such as atopic dermatitis and alopecia areata, and ADX-097 for complement-mediated disorders, with a Phase 2 trial in ANCA-associated vasculitis planned for early 2025. Homology Medicines Inc. is a US-based clinical-stage genetic medicines company focused on rare diseases.

Regional Outlook

North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, disease management, and patient counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market also includes sales of biologic therapies, plasma exchange equipment, diagnostic test kits, targeted oral therapies, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report 2026?

The antineutrophil cytoplasmic antibody (anca) associated vasculitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antineutrophil cytoplasmic antibody (anca) associated vasculitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.